IceCure Medical (NASDAQ:ICCM - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 28th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.75 million for the quarter.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
IceCure Medical Stock Performance
ICCM traded up $0.04 during trading on Friday, hitting $1.06. The stock had a trading volume of 133,179 shares, compared to its average volume of 471,868. The firm has a market cap of $58.83 million, a PE ratio of -3.66 and a beta of 0.41. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.66. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.13.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $2.50 target price on shares of IceCure Medical in a report on Friday, March 28th.
Check Out Our Latest Report on IceCure Medical
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Articles

Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.